1. Introduction
Over the last 40 years, kidney transplantation has become the preferred method of treatment for end-stage renal disease (ESRD). Acute rejection is the most important cause of kidney allograft failure. The conventional anti-rejection therapy includes intravenous steroids and antithymocyte globulin (ATG) (1, 2). In cases of antibody mediated rejection, therapies like plasmapheresis, intravenous imunoglobulin (IVIG), rituximab and/or bortezomib are often added (1-3). Local graft irradiation (LGI) is a lesser known therapy for the treatment of rejection. The immunosuppressive properties of the radiation therapy have been known for a long time. These properties are currently harnessed to eliminate lymphocytes in blood transfusion products in order to prevent transfusion associated complications like graft versus host disease (4). Radiation therapy has also been used in the field of renal transplantation since its early days (5). Initial studies showed improved graft survival with different methods of radiation such as extracorporeal blood irradiation (6), total lymphoid irradiation (7) and local graft irradiation (LGI) (8). Despite the initial promising results in small retrospective studies (8), later randomized trials did not show the beneficial effects of LGI for treatment of acute allograft rejection as first line adjunct therapy added to a conventional anti-rejection regimen like antithymocyte globulin (ATG) and steroids (9-11). However, the efficacy of LGI as a second line therapy after failure of conventional antirejection treatment has been more successful (12-17). In this study, we have reported our experience with 6 patients with acute kidney allograft rejection who were treated with LGI as a second line therapy. In addition, we have reviewed the previous literature on the use of LGI for acute kidney allograft rejection. This study was approved by Institutional Review Board of our institution and was done in accordance with the Helsinki Declaration of 1975 (as revised in 1983). In this study the charts of all patients with acute kidney allograft rejection who were treated with LGI at our center were retrospectively reviewed. Rejection refractory to medical therapy was defined as an acute rejection that did not respond to conventional anti-rejection therapy (antithymocyte globulin [ATG] or muromonab-CD3 per physician’s discretion in addition to intravenous steroids) with failure of serum creatinine to trend down until at least 1 week after the completion of anti-rejection therapy. IVIG was also given to patients with positive donor specific antibody (DSA) levels which were defined as a mean fluorescence intensity ≥ 2000. The DSA level were measured by a Luminex analyzer (Luminex Corporation, Austin, TX, USA). Episodes of acute rejection were confirmed by renal biopsy. The dose range of LGI treatment varied from 600–800 cGy given in the fractions of 150 cGy to 200 cGy daily for 4 days using either 6MV and/or 18MV photons.
2. Case Presentation
The patients’ demographics, clinical characteristics, radiotherapy doses and final outcomes are shown in Table 1. Per our center’s protocol all patients except patient No 4 received 7-10 doses of ATG (1.5 mg/kg IV daily) or 10 doses of muromonab-CD3 (5 mg IV daily) along with high dose IV steroids for treatment of acute allograft rejection. Except for patient No 6, the kidney function improved temporarily in all patients who were treated with LGI. Our patients’ kidney allograft survival at 1, 3, 6 and 12 months was 83%, 83%, 33% and 17%, respectively. Patient No 4 was diagnosed with cryptococcal meningitis 3 days after biopsy proven allograft rejection, and therefore he was treated with IV steroids and ATG for only 3 days. He was switched to LGI on day 5 with good response.
| Patients No. | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Age at time of transplantation, y | 28 | 26 | 21 | 38 | 32 | 35 |
| Type of kidney transplantation | Deceased donor | Living donor | Living donor | Deceased donor (simultaneous kidney/pancreas transplant) | Living donor | Deceased donor |
| Etiology of kidney disease | Hypertensive nephropathy | IgA nephropathy | Reflux nephropathy | Diabetic nephropathy | Diabetic nephropathy | Hypertensive nephropathy |
| Baseline serum creatinine range, mg/dL | 2.0-2.4 | 1.5-2.1 | 2.5-3 | 2.5-2.7 | 1.5-2.1 | 2.5-3.2 |
| Time from kidney transplantation to rejection, mo | 54 | 22 | 36 | 29 | 75 | 21 |
| Allograft kidney biopsy | Grade 1A rejection, Peritubular capillaritis, C4d+, No fibrosis | Grade 1B rejection, Peritubular capillaritis, C4d+, No fibrosis | Grade 1B rejection, Thrombotic microangiopathy, C4d+, Minimal fibrosis | Grade 1B rejection, C4d-, Moderate fibrosis | Grade 1A rejection, C4d-, Moderate fibrosis | Grade 1B rejection, Peritubular capillaritis, C4d-, No fibrosis |
| DSA | + | - | + | - | - | + |
| Medical Management | ATG (1.5 mg/kg × 8 doses), IVIG (50 g × 1 dose), IV steroids taper | Muromonab-CD3 (5 mg × 10 doses), IV steroids taper | ATG (1.5 mg/kg × 10 doses), IVIG (40 g × 1 dose), IV steroids taper | ATG (1.5 mg/kg × 3 doses), IV steroids taper | ATG (1.5 mg/kg × 7 doses), IV steroids taper | ATG (1.5 mg/kg × 10 doses), IVIG (40 g × 2 doses), IV steroids taper |
| Maintenance therapy before rejection | Mycophenolic acid 720 mg BID, tacrolimus 16 mg BID, prednisone 2.5 mg QD | Mycophenolate mofetil 1000 mg BID, tacrolimus 2 mg BID, prednisone 2.5 mg QD | Mycophenolate mofetil 1000 mg BID, tacrolimus 2 mg BID, prednisone 20 mg QD | Sirolimus 1 mg QD, tacrolimus 1 mg BID, prednisone 20 mg QD | Mycophenolate mofetil 1000 mg BID, tacrolimus 2 mg BID, prednisone 10 mg QD | Mycophenolate mofetil 750 mg BID, tacrolimus 3 mg BID, prednisone 2.5 mg QD |
| Prior Rejections | 4 | 3 | 3 | 6 | 4 | 0 |
| Time difference between biopsy and radiotherapy, d | 15 | 17 | 20 | 5 | 16 | 18 |
| LGI Dose | 200 cGy/d × 4 using 6 MV/18 MV photons | 150 cGy/d × 4 using 18 MV photons | 150 cGy/d × 4 using 6 MV photons | 200 cGy/d × 4 using 6 MV/18 MV photons | 200 cGy/d × 4 using 6 MV/18 MV photons | 200 cGy/d × 4 doses using 6 MV photons |
| Change in Serum creatinine, mg/dL within a month post-LGI | Serum Cr decreased from 5.2 mg/dL to 4.4 mg/dL a month after radiotherapy | Serum Cr decreased from 4.3 mg/dL to 3.3 mg/dL at 2 weeks | Serum Cr decreased from 5.9 mg/dL to 4.8 mg/dL at 2 weeks | Serum Cr decreased from 6.9 mg/dL to 3.8 mg/dL at 3 weeks | Serum Cr remained stable between 3.9-4.1 mg/dL. | Serum Cr increased from 7.0 mg/dL to 7.7 mg/dL a week after LGI |
| Outcome post LGI | Renal function has remained stable since LGI | Renal function stabilized for 2 months but deteriorated at 3 months post-LGI and patient initiated dialysis | Renal function stabilized for 6 months but deteriorated at 7 months post LGI and patient initiated dialysis | Renal function stabilized for 2 months but deteriorated at 3 months post LGI and patient initiated dialysis | Renal function stabilized for 3 months and but deteriorated at 4 months post- LGI, patient initiated dialysis | Renal function did not improve post-LGI therapy and patient initiated dialysis 1 week post-LGI |
| Graft survival, post-LGI, months | Kidney allograft functional till last follow-up of 24 months | 3 | 7 | 3 | 4 | 0 |
The Demographics, Clinical Characteristics, Radiotherapy Doses and Final Outcomes of Patients With Acute Kidney Allograft Rejection Refractory to Medical Therapy Treated With LGI a
3. Discussion
Our results suggest that for patients with refractory acute kidney allograft rejection LGI may be considered as a second line therapy to conventional antirejection therapy including intravenous steroids and ATG. In our study, 5 out of 6 patients with refractory rejection responded favorably to LGI. In addition, patient No.4 had concomitant acute rejection and cryptococcal meningitis and responded well to LGI suggesting that LGI may also be indicated for patients with acute rejection when systemic immunosuppression is contraindicated as in the setting of superimposed serious systemic infection. In our study, LGI was found to be safe and without any major adverse effect. Although the initial reports on using LGI as an adjuvant therapy for acute rejection were encouraging (8), 3 later randomized trials did not show the efficacy of LGI as an addition to the chemical immunosuppressive therapies in the first line of treatment for acute kidney rejection (9-11). Later studies showed that LGI could be used as a second line therapy when the acute kidney rejection failed to respond to medical immunosuppressive therapy (Table 2). In 1984, Halperin et al. (12) demonstrated that in 53 patients with acute allograft rejection resistant to medical therapy, radiotherapy resulted in improvement or stabilization of renal function in 42% of the patients a month after LGI. But one year post-LGI, only 21% of these allografts were still functional. In this study, 10 patients with acute allograft rejection in whom immunosuppressive therapy was contraindicated because of either systemic infections or hematologic dyscrasias received LGI; 1 month and 1 year graft survival rates in this group were 90% and 40%, respectively. Later, Noyes et al. (14) and Nuyttens et al. (15) reported a 1 year graft survival of 49% and 50%, respectively, in patients who had acute rejection refractory to medical therapy and who received LGI. In a study by Chen et al. (17) which mostly included patients with acute allograft rejection resistant to medical therapy, 1 year graft survival rate was 60%. Wahl et al. (16) reported a 1 month graft survival of 63%, but the 1 year graft survival was poor at 31%. Similar to previous reports, our study also shows a good short term graft survival (83% at 1 and 3 months) but poor long term graft survival (17% at 1 year) when LGI is given as a second line agent for refractory rejection.
The mechanism of action of LGI in the treatment of rejection appears to be the elimination of lymphocytes. Dividing cells like lymphocytes, both in circulation and in tissues, have been shown to be particularly sensitive to radiation therapy (18). Radiation can directly damage DNA; however, generation of free reactive oxygen species from the radiolysis of water by radiation is the most important cause of DNA damage and cell death. The T-cells involved in acute cellular rejection are located in the transplanted kidney, but plasma cells that produce antibodies involved in antibody mediated rejection are mostly located in the lymph nodes and bone marrow (19). Therefore, by preferentially targeting T-cells located in the kidney, LGI is probably more effective against acute cellular rejection compared with antibody mediated rejection. Compared with sensitive dividing cells like lymphocytes, non-dividing cells like renal cells are less sensitive to radiation therapy (18). Moreover, the dose of radiation in LGI is low. Therefore, LGI appears to be safe in the treatment of acute kidney allograft rejection without major side effects like radiation nephritis (10, 16).
LGI may be tried as a second line therapy for treatment of kidney allograft rejection refractory to conventional anti-rejection medical therapy. In addition, LGI may be a useful modality for treatment of kidney allograft rejection when systemic immunosuppression is contraindicated due to concomitant severe and serious infection. The benefits of LGI should be confirmed in future prospective randomized controlled trials.
| Author | Number of Patients | Selection Criteria | Dose Range, cGy | Median Dose, cGy | One Month Graft Survival Post-LGI, % | One Year Graft Survival Post-LGI, % |
|---|---|---|---|---|---|---|
| Halperin et al. (12) | 53 | Refractory acute allograft rejection | 300-1200 | 600 | 42 | 21 |
| 10 | Acute allograft rejection with contraindicated immunosuppressive therapy due to systemic infection or hematologic dyscrasias | 300-1200 | 600 | 90 | 40 | |
| Jagetia et al. (13) | 6 | Refractory acute allograft rejection | 450-600 | 450 | 50 | 17 |
| Noyes et al. (14) | 72 | Refractory acute allograft rejection | 800 | 800 | NA | 49 |
| Chen et al. (17) | 53 | Refractory acute allograft rejection (75 % of patients) | 600 | 600 | 83 | 60 |
| Nuyttens et al. (15) | 20 | Refractory acute allograft rejection | 450 | 450 | NA | 50 |
| Wahl et al. (16) | 33 | Refractory acute allograft rejection | 800 | 800 | 63 | 31 |
| Current study | 6 | Refractory acute allograft rejection | 800–600 | 733 | 83 | 17 |
